

Anti-BCMA & CD3 Reference Antibody (Linvoseltamab)

Catalog # APR11571

Product Information


Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	Q02223 & P07766
Reactivity	Human
Clonality	Bispecific
Isotype	IgG-like

Additional Information


Target/Specificity	TNFRSF17 / BCMA / CD269,CD3
Expression system	CHO

Protein Information

Images




Anti-BCMA & CD3 Reference Antibody (Linvoseltamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.




The purity of Anti-BCMA & CD3 Reference Antibody (Linvoseltamab) is 97.71%, determined by SEC-HPLC.


Linvoseltamab bound to BCMA protein, and then rebounded to secondary antibodies (Anti-human-IgG-Fc-HRP), and read OD450. As shown in fig, Linvoseltamab bound to huBCMA-ECD-His, and the EC50 was 0.096 nM.




Livoseltamab bound to Jurkat cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcy PE), and test by flow cytometry. As shown in fig, Linvoseltamab bound to Jurket cells, and the EC50 was 11.160 nM.




Livoseltamab bound to huBCMA-HEK293 cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcy PE), and test by flow cytometry. As shown in fig, Linvoseltamab bound to huBCMA-HEK293 cells, and the EC50 was 2.486 nM.



Co-incubation of Linvoseltamab with Jurkat cells, then with the addition of huBCMA-HEK293 cells for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Linvoseltamab was able to activate the NF-AT signaling pathway, and the EC50 was 0.678 nM.



The detected molecular weight of Anti-BCMA & CD3 Reference Antibody (Livoseltamab) is 145.95 kDa.



Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.